Anixa Biosciences to Present at the B. Riley Oncology Investor Conference
Anixa Biosciences, a biotechnology firm focused on cancer and infectious disease treatments, announced that CEO Dr. Amit Kumar will present at B. Riley's Inaugural Oncology Investor Conference on January 20-21, 2021. Dr. Kumar will participate in a fireside chat to discuss the company's recent achievements and future milestones. The presentation, scheduled for January 21 at 10:30 a.m. PST, will be accessible via live webcast for registered attendees. Anixa's innovative portfolio includes cancer immunotherapy and vaccines for breast and ovarian cancer. More details can be found on Anixa's website.
- None.
- None.
SAN JOSE, Calif., Jan. 13, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at B. Riley's Inaugural Oncology Investor Conference to be held January 20-21, 2021.
Dr. Kumar will participate in a fireside chat presentation to discuss Anixa's recent accomplishments and anticipated milestones. Company management will also be available to participate in online one-on-one meetings with investors who are registered to attend the conference.
Anixa's presentation will be live webcast at 10:30 a.m. PST on January 21, 2021. The presentation will be open to registered conference attendees, institutional investors and investor relations professionals, who may register to view the live webcast at https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup. After completion of the event, a replay of the presentation will be publicly available on the Anixa website at https://ir.anixa.com/events.
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Investor contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Media contact:
Sherry Ash
anixapress@gmail.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-b-riley-oncology-investor-conference-301207339.html
SOURCE Anixa Biosciences, Inc.
FAQ
What will Anixa Biosciences present at the B. Riley Oncology Investor Conference?
When is Anixa Biosciences' presentation at the B. Riley Conference?
How can I watch Anixa Biosciences' presentation live?
What technologies does Anixa Biosciences focus on?
Where can I find more information about Anixa Biosciences?
